{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-084098","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.862200+00:00","generated_at":"2026-05-19T15:37:36.318527+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Axsome launches SYMBRAVO for acute migraine treatment in U.S.","bullets":["SYMBRAVO (meloxicam/rizatriptan) now available by prescription for acute migraine with or without aura in adults.","Novel multi-mechanistic approach targeting multiple migraine pathways; rapid pain freedom at 2 hours vs placebo, sustained up to 24 hours.","Axsome launches SYMBRAVO On My Side patient support program including savings card for eligible patients.","SYMBRAVO uses Axsome's patented MoSEIC technology; migraine affects ~40M Americans, 63% not satisfied with current treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-084098","json":"https://secwatch.observer/filing/0000950170-25-084098.json","markdown":"https://secwatch.observer/filing/0000950170-25-084098.md","text":"https://secwatch.observer/filing/0000950170-25-084098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025084098/0000950170-25-084098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025084098/axsm-20250610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T15:37:36.318527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}